The National Amyotrophic Lateral Sclerosis Registry

Study Purpose:

The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.

Disease:

Amyotrophic Lateral Sclerosis (ALS),  Familial ALS,  Sporadic ALS

Study Type:

Observational Study

Study Category:

Epidemiology

Study Status:

Enrolling

Phase:

Not Applicable

Study Chair(s)/Principal Investigator(s):

Paul Mehta, MD, Centers for Disease Control and Prevention

Clinicaltrials.gov ID (11 digit #):

NCT01772602

Neals Affiliated?

No

Coordinating Center Contact Information


Paul Mehta, MD / .(JavaScript must be enabled to view this email address) / 770-488-0556
Kevin Horton, DrPH, MSPH / .(JavaScript must be enabled to view this email address) / 770-488-1555
Atlanta, Georgia 30333 United States

Full Study Summary:

Study Sponsor:

Centers for Disease Control and Prevention

Participant Duration:

Estimated Enrollment:

13,000

Estimated Study Start Date:

10/01/2010

Estimated Study Completion Date:

12/31/2020

Posting Last Modified Date:

02/29/2016

Date Study Added to alsconsortium.org:

01/22/2013
  • Eligibility Criteria

    Gender:

    Female, Male

    Minimum Age:

    18

    Maximum Age:

    N/A

    Time since Symptom Onset:

    Time since Diagnosis:

    Can participants use Riluzole?

    Yes


    Inclusion Criteria:
    ALS cases in the United States
    U.S. citizens 18 years of age or older

  • Site Contact Information